Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Treasury Shares (2016 - 2025)

VYNE Therapeutics' Treasury Shares history spans 9 years, with the latest figure at $450916.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 39.94% year-over-year to $450916.0; the TTM value through Dec 2025 reached $450916.0, down 39.94%, while the annual FY2025 figure was $450916.0, 39.94% down from the prior year.
  • Treasury Shares reached $450916.0 in Q4 2025 per VYNE's latest filing, down from $750715.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $750715.0 in Q4 2024 to a low of $70133.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $363271.8, with a median of $450916.0 recorded in 2025.
  • Peak YoY movement for Treasury Shares: plummeted 90.25% in 2021, then skyrocketed 451.3% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $70133.0 in 2021, then grew by 19.22% to $83616.0 in 2022, then surged by 451.3% to $460979.0 in 2023, then soared by 62.85% to $750715.0 in 2024, then crashed by 39.94% to $450916.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Treasury Shares are $450916.0 (Q4 2025), $750715.0 (Q4 2024), and $460979.0 (Q4 2023).